APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Oral Vaccine for Human

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Oral Vaccine for Human Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

Report ID 174020310330 December 2025197 pages

Choose your research edition.

Industry ResearchOral Vaccine for Human Industry Research Report 2026131 pages · $2,950 USDIndustry Growth & TrendsGlobal Oral Vaccine for Human Industry Growth and Trends Forecast to 2032110 pages · $3,450 USDMarket StructureGlobal Oral Vaccine for Human Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032197 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Oral Vaccine for Human Market Outlook and Growth Opportunities 2026193 pages · $4,250 USDMarket Analysis & ForecastGlobal Oral Vaccine for Human Market Analysis and Forecast 2026-2032197 pages · $4,950 USD

Market perspective

The global Oral Vaccine for Human market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Oral Vaccine for Human is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Oral Vaccine for Human is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Oral Vaccine for Human is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Oral Vaccine for Human is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Oral Vaccine for Human include Bibcol, Bio-Med, EuBiologics, Halfkin Bio-Pharmaceuticals, Panacea Biotec Ltd, PaxVax, Serum Institute, Vabiotech and Valneva, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Oral Vaccine for Human market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Oral Vaccine for Human and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Oral Vaccine for Human sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Oral Vaccine for Human market size, projected growth trends, production technologies, key applications, and end-use industries.

Oral Vaccine for Human Segment by Company

Bibcol

Bio-Med

EuBiologics

Halfkin Bio-Pharmaceuticals

Panacea Biotec Ltd

PaxVax

Serum Institute

Vabiotech

Valneva

Tiantan Biological

GSK

Merck

Sanofi

Shanghai United Cell

Lanzhou Institute

Oral Vaccine for Human Segment by Type

Cholera Vaccine

Oral Polio Vaccine

Rotavirus Vaccine

Other

Oral Vaccine for Human Segment by Application

Public

Private

Oral Vaccine for Human Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Oral Vaccine for Human market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Oral Vaccine for Human and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Oral Vaccine for Human.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Oral Vaccine for Human market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Oral Vaccine for Human manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Oral Vaccine for Human in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Oral Vaccine for Human in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Oral Vaccine for Human Industry Trends Table 2. Oral Vaccine for Human Industry Drivers Table 3. Oral Vaccine for Human Industry Opportunities and Challenges Table 4. Oral Vaccine for Human Industry Restraints Table 5. Global Oral Vaccine for Human Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Oral Vaccine for Human Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Oral Vaccine for Human Sales by Manufacturers (K Units) & (2021-2026) Table 8. Global Oral Vaccine for Human Sales Market Share by Manufacturers Table 9. Global Oral Vaccine for Human Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global Oral Vaccine for Human Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Oral Vaccine for Human Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Oral Vaccine for Human Manufacturers, Product Type & Application Table 13. Global Oral Vaccine for Human Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Oral Vaccine for Human by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Cholera Vaccine Table 17. Major Manufacturers of Oral Polio Vaccine Table 18. Major Manufacturers of Rotavirus Vaccine Table 19. Major Manufacturers of Other Table 20. Global Oral Vaccine for Human Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 21. Global Oral Vaccine for Human Sales by Type (2021-2026) & (K Units) Table 22. Global Oral Vaccine for Human Sales by Type (2027-2032) & (K Units) Table 23. Global Oral Vaccine for Human Sales Market Share by Type (2021-2026) Table 24. Global Oral Vaccine for Human Sales Market Share by Type (2027-2032) Table 25. Global Oral Vaccine for Human Revenue by Type 2021 VS 2025 VS 2032 (K Units) Table 26. Global Oral Vaccine for Human Revenue by Type (2021-2026) & (K Units) Table 27. Global Oral Vaccine for Human Revenue by Type (2027-2032) & (K Units) Table 28. Global Oral Vaccine for Human Revenue Market Share by Type (2021-2026) Table 29. Global Oral Vaccine for Human Revenue Market Share by Type (2027-2032) Table 30. Major Manufacturers of Public Table 31. Major Manufacturers of Private Table 32. Global Oral Vaccine for Human Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 33. Global Oral Vaccine for Human Sales by Application (2021-2026) & (K Units) Table 34. Global Oral Vaccine for Human Sales by Application (2027-2032) & (K Units) Table 35. Global Oral Vaccine for Human Sales Market Share by Application (2021-2026) Table 36. Global Oral Vaccine for Human Sales Market Share by Application (2027-2032) Table 37. Global Oral Vaccine for Human Revenue by Application 2021 VS 2025 VS 2032 (K Units) Table 38. Global Oral Vaccine for Human Revenue by Application (2021-2026) & (K Units) Table 39. Global Oral Vaccine for Human Revenue by Application (2027-2032) & (K Units) Table 40. Global Oral Vaccine for Human Revenue Market Share by Application (2021-2026) Table 41. Global Oral Vaccine for Human Revenue Market Share by Application (2027-2032) Table 42. Global Oral Vaccine for Human Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 43. Global Oral Vaccine for Human Sales by Region (2021-2026) & (K Units) Table 44. Global Oral Vaccine for Human Sales Market Share by Region (2021-2026) Table 45. Global Oral Vaccine for Human Sales Forecasted by Region (2027-2032) & (K Units) Table 46. Global Oral Vaccine for Human Sales Forecasted Market Share by Region (2027-2032) Table 47. North America Oral Vaccine for Human Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 48. North America Oral Vaccine for Human Sales by Country (2021-2026) & (K Units) Table 49. North America Oral Vaccine for Human Sales by Country (2027-2032) & (K Units) Table 50. Europe Oral Vaccine for Human Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 51. Europe Oral Vaccine for Human Sales by Country (2021-2026) & (K Units) Table 52. Europe Oral Vaccine for Human Sales by Country (2027-2032) & (K Units) Table 53. Asia Pacific Oral Vaccine for Human Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 54. Asia Pacific Oral Vaccine for Human Sales by Country (2021-2026) & (K Units) Table 55. Asia Pacific Oral Vaccine for Human Sales by Country (2027-2032) & (K Units) Table 56. South America, Middle East and Africa Oral Vaccine for Human Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 57. South America, Middle East and Africa Oral Vaccine for Human Sales by Country (2021-2026) & (K Units) Table 58. South America, Middle East and Africa Oral Vaccine for Human Sales by Country (2027-2032) & (K Units) Table 59. Global Oral Vaccine for Human Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 60. Global Oral Vaccine for Human Revenue by Region (2021-2026) & (US$ Million) Table 61. Global Oral Vaccine for Human Revenue by Region (2027-2032) & (US$ Million) Table 62. Global Oral Vaccine for Human Revenue Market Share by Region (2021-2026) Table 63. Global Oral Vaccine for Human Revenue Market Share by Region (2027-2032) Table 64. Bibcol Company Information Table 65. Bibcol Business Overview Table 66. Bibcol Oral Vaccine for Human Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 67. Bibcol Oral Vaccine for Human Product Portfolio Table 68. Bibcol Recent Development Table 69. Bio-Med Company Information Table 70. Bio-Med Business Overview Table 71. Bio-Med Oral Vaccine for Human Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 72. Bio-Med Oral Vaccine for Human Product Portfolio Table 73. Bio-Med Recent Development Table 74. EuBiologics Company Information Table 75. EuBiologics Business Overview Table 76. EuBiologics Oral Vaccine for Human Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 77. EuBiologics Oral Vaccine for Human Product Portfolio Table 78. EuBiologics Recent Development Table 79. Halfkin Bio-Pharmaceuticals Company Information Table 80. Halfkin Bio-Pharmaceuticals Business Overview Table 81. Halfkin Bio-Pharmaceuticals Oral Vaccine for Human Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 82. Halfkin Bio-Pharmaceuticals Oral Vaccine for Human Product Portfolio Table 83. Halfkin Bio-Pharmaceuticals Recent Development Table 84. Panacea Biotec Ltd Company Information Table 85. Panacea Biotec Ltd Business Overview Table 86. Panacea Biotec Ltd Oral Vaccine for Human Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 87. Panacea Biotec Ltd Oral Vaccine for Human Product Portfolio Table 88. Panacea Biotec Ltd Recent Development Table 89. PaxVax Company Information Table 90. PaxVax Business Overview Table 91. PaxVax Oral Vaccine for Human Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 92. PaxVax Oral Vaccine for Human Product Portfolio Table 93. PaxVax Recent Development Table 94. Serum Institute Company Information Table 95. Serum Institute Business Overview Table 96. Serum Institute Oral Vaccine for Human Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 97. Serum Institute Oral Vaccine for Human Product Portfolio Table 98. Serum Institute Recent Development Table 99. Vabiotech Company Information Table 100. Vabiotech Business Overview Table 101. Vabiotech Oral Vaccine for Human Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 102. Vabiotech Oral Vaccine for Human Product Portfolio Table 103. Vabiotech Recent Development Table 104. Valneva Company Information Table 105. Valneva Business Overview Table 106. Valneva Oral Vaccine for Human Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 107. Valneva Oral Vaccine for Human Product Portfolio Table 108. Valneva Recent Development Table 109. Tiantan Biological Company Information Table 110. Tiantan Biological Business Overview Table 111. Tiantan Biological Oral Vaccine for Human Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 112. Tiantan Biological Oral Vaccine for Human Product Portfolio Table 113. Tiantan Biological Recent Development Table 114. GSK Company Information Table 115. GSK Business Overview Table 116. GSK Oral Vaccine for Human Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 117. GSK Oral Vaccine for Human Product Portfolio Table 118. GSK Recent Development Table 119. Merck Company Information Table 120. Merck Business Overview Table 121. Merck Oral Vaccine for Human Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 122. Merck Oral Vaccine for Human Product Portfolio Table 123. Merck Recent Development Table 124. Sanofi Company Information Table 125. Sanofi Business Overview Table 126. Sanofi Oral Vaccine for Human Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 127. Sanofi Oral Vaccine for Human Product Portfolio Table 128. Sanofi Recent Development Table 129. Shanghai United Cell Company Information Table 130. Shanghai United Cell Business Overview Table 131. Shanghai United Cell Oral Vaccine for Human Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 132. Shanghai United Cell Oral Vaccine for Human Product Portfolio Table 133. Shanghai United Cell Recent Development Table 134. Lanzhou Institute Company Information Table 135. Lanzhou Institute Business Overview Table 136. Lanzhou Institute Oral Vaccine for Human Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 137. Lanzhou Institute Oral Vaccine for Human Product Portfolio Table 138. Lanzhou Institute Recent Development Table 139. Key Raw Materials Table 140. Raw Materials Key Suppliers Table 141. Oral Vaccine for Human Distributors List Table 142. Oral Vaccine for Human Customers List Table 143. Research Programs/Design for This Report Table 144. Authors List of This Report Table 145. Secondary Sources Table 146. Primary Sources List of Figures Figure 1. Oral Vaccine for Human Product Image Figure 2. Global Oral Vaccine for Human Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Oral Vaccine for Human Market Size (2021-2032) & (US$ Million) Figure 4. Global Oral Vaccine for Human Sales (2021-2032) & (K Units) Figure 5. Global Oral Vaccine for Human Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 Oral Vaccine for Human Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Cholera Vaccine Image Figure 9. Oral Polio Vaccine Image Figure 10. Rotavirus Vaccine Image Figure 11. Other Image Figure 12. Global Oral Vaccine for Human Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 13. Global Oral Vaccine for Human Sales Market Share 2021 VS 2025 VS 2032 Figure 14. Global Oral Vaccine for Human Sales Market Share by Type (2021-2032) Figure 15. Global Oral Vaccine for Human Revenue by Type (2021 VS 2025 VS 2032) & (K Units) Figure 16. Global Oral Vaccine for Human Revenue Market Share 2021 VS 2025 VS 2032 Figure 17. Global Oral Vaccine for Human Revenue Market Share by Type (2021-2032) Figure 18. Public Image Figure 19. Private Image Figure 20. Global Oral Vaccine for Human Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 21. Global Oral Vaccine for Human Sales Market Share 2021 VS 2025 VS 2032 Figure 22. Global Oral Vaccine for Human Sales Market Share by Application (2021-2032) Figure 23. Global Oral Vaccine for Human Revenue by Application (2021 VS 2025 VS 2032) & (K Units) Figure 24. Global Oral Vaccine for Human Revenue Market Share 2021 VS 2025 VS 2032 Figure 25. Global Oral Vaccine for Human Revenue Market Share by Application (2021-2032) Figure 26. North America Oral Vaccine for Human Sales and Growth Rate (2021-2032) & (K Units) Figure 27. North America Oral Vaccine for Human Sales Market Share by Country (2021-2032) Figure 28. U.S. Oral Vaccine for Human Sales and Growth Rate (2021-2032) & (K Units) Figure 29. Canada Oral Vaccine for Human Sales and Growth Rate (2021-2032) & (K Units) Figure 30. Mexico Oral Vaccine for Human Sales and Growth Rate (2021-2032) & (K Units) Figure 31. Europe Oral Vaccine for Human Sales and Growth Rate (2021-2032) & (K Units) Figure 32. Europe Oral Vaccine for Human Sales Market Share by Country (2021-2032) Figure 33. Germany Oral Vaccine for Human Sales and Growth Rate (2021-2032) & (K Units) Figure 34. France Oral Vaccine for Human Sales and Growth Rate (2021-2032) & (K Units) Figure 35. U.K. Oral Vaccine for Human Sales and Growth Rate (2021-2032) & (K Units) Figure 36. Italy Oral Vaccine for Human Sales and Growth Rate (2021-2032) & (K Units) Figure 37. Netherlands Oral Vaccine for Human Sales and Growth Rate (2021-2032) & (K Units) Figure 38. Asia Pacific Oral Vaccine for Human Sales and Growth Rate (2021-2032) & (K Units) Figure 39. Asia Pacific Oral Vaccine for Human Sales Market Share by Country (2021-2032) Figure 40. China Oral Vaccine for Human Sales and Growth Rate (2021-2032) & (K Units) Figure 41. Japan Oral Vaccine for Human Sales and Growth Rate (2021-2032) & (K Units) Figure 42. South Korea Oral Vaccine for Human Sales and Growth Rate (2021-2032) & (K Units) Figure 43. Southeast Asia Oral Vaccine for Human Sales and Growth Rate (2021-2032) & (K Units) Figure 44. India Oral Vaccine for Human Sales and Growth Rate (2021-2032) & (K Units) Figure 45. Australia Oral Vaccine for Human Sales and Growth Rate (2021-2032) & (K Units) Figure 46. South America, Middle East and Africa Oral Vaccine for Human Sales and Growth Rate (2021-2032) & (K Units) Figure 47. South America, Middle East and Africa Oral Vaccine for Human Sales Market Share by Country (2021-2032) Figure 48. Brazil Oral Vaccine for Human Sales and Growth Rate (2021-2032) & (K Units) Figure 49. South Africa Oral Vaccine for Human Sales and Growth Rate (2021-2032) & (K Units) Figure 50. Saudi Arabia Oral Vaccine for Human Sales and Growth Rate (2021-2032) & (K Units) Figure 51. Turkey Oral Vaccine for Human Sales and Growth Rate (2021-2032) & (K Units) Figure 52. Argentina Oral Vaccine for Human Sales and Growth Rate (2021-2032) & (K Units) Figure 53. UAE Oral Vaccine for Human Sales and Growth Rate (2021-2032) & (K Units) Figure 54. Egypt Oral Vaccine for Human Sales and Growth Rate (2021-2032) & (K Units) Figure 55. Chile Oral Vaccine for Human Sales and Growth Rate (2021-2032) & (K Units) Figure 56. Global Oral Vaccine for Human Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 57. Global Oral Vaccine for Human Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 58. North America Oral Vaccine for Human Revenue (2021-2032) & (US$ Million) Figure 59. North America Oral Vaccine for Human Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 60. Europe Oral Vaccine for Human Revenue (2021-2032) & (US$ Million) Figure 61. Europe Oral Vaccine for Human Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 62. Asia-Pacific Oral Vaccine for Human Revenue (2021-2032) & (US$ Million) Figure 63. Asia-Pacific Oral Vaccine for Human Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 64. South America, Middle East and Africa Oral Vaccine for Human Revenue (2021-2032) & (US$ Million) Figure 65. South America, Middle East and Africa Oral Vaccine for Human Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 66. Oral Vaccine for Human Value Chain Figure 67. Manufacturing Cost Structure Figure 68. Oral Vaccine for Human Production Mode & Process Figure 69. Direct Comparison with Distribution Share Figure 70. Distributors Profiles Figure 71. Years Considered Figure 72. Research Process Figure 73. Key Executives Interviewed

Scope & coverage.

Types
  • Cholera Vaccine
  • Oral Polio Vaccine
  • Rotavirus Vaccine
  • Other
Applications
  • Public
  • Private
Companies covered
  • Bibcol
  • Bio-Med
  • EuBiologics
  • Halfkin Bio-Pharmaceuticals
  • Panacea Biotec Ltd
  • PaxVax
  • Serum Institute
  • Vabiotech
  • Valneva
  • Tiantan Biological
  • GSK
  • Merck
  • Sanofi
  • Shanghai United Cell
  • Lanzhou Institute

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Oral Vaccine for Human Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Oral Vaccine for Human Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Oral Vaccine for Human Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Oral Vaccine for Human Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Oral Vaccine for Human Market Dynamics
  1. 2.1 Oral Vaccine for Human Industry Trends
  2. 2.2 Oral Vaccine for Human Industry Drivers
  3. 2.3 Oral Vaccine for Human Industry Opportunities and Challenges
  4. 2.4 Oral Vaccine for Human Industry Restraints
3 Oral Vaccine for Human Market by Manufacturers
  1. 3.1 Global Oral Vaccine for Human Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Oral Vaccine for Human Sales by Manufacturers (2021-2026)
  3. 3.3 Global Oral Vaccine for Human Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Oral Vaccine for Human Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Oral Vaccine for Human Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Oral Vaccine for Human Manufacturers, Product Type & Application
  7. 3.7 Global Oral Vaccine for Human Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Oral Vaccine for Human Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Oral Vaccine for Human Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Oral Vaccine for Human Tier 1, Tier 2, and Tier 3
4 Oral Vaccine for Human Market by Type
  1. 4.1 Oral Vaccine for Human Type Introduction
  2. 4.1.1 Cholera Vaccine
  3. 4.1.2 Oral Polio Vaccine
  4. 4.1.3 Rotavirus Vaccine
  5. 4.1.4 Other
  6. 4.2 Global Oral Vaccine for Human Sales by Type
  7. 4.2.1 Global Oral Vaccine for Human Sales by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global Oral Vaccine for Human Sales by Type (2021-2032)
  9. 4.2.3 Global Oral Vaccine for Human Sales Market Share by Type (2021-2032)
  10. 4.3 Global Oral Vaccine for Human Revenue by Type
  11. 4.3.1 Global Oral Vaccine for Human Revenue by Type (2021 VS 2025 VS 2032)
  12. 4.3.2 Global Oral Vaccine for Human Revenue by Type (2021-2032)
  13. 4.3.3 Global Oral Vaccine for Human Revenue Market Share by Type (2021-2032)
5 Oral Vaccine for Human Market by Application
  1. 5.1 Oral Vaccine for Human Application Introduction
  2. 5.1.1 Public
  3. 5.1.2 Private
  4. 5.2 Global Oral Vaccine for Human Sales by Application
  5. 5.2.1 Global Oral Vaccine for Human Sales by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Oral Vaccine for Human Sales by Application (2021-2032)
  7. 5.2.3 Global Oral Vaccine for Human Sales Market Share by Application (2021-2032)
  8. 5.3 Global Oral Vaccine for Human Revenue by Application
  9. 5.3.1 Global Oral Vaccine for Human Revenue by Application (2021 VS 2025 VS 2032)
  10. 5.3.2 Global Oral Vaccine for Human Revenue by Application (2021-2032)
  11. 5.3.3 Global Oral Vaccine for Human Revenue Market Share by Application (2021-2032)
6 Global Oral Vaccine for Human Sales by Region
  1. 6.1 Global Oral Vaccine for Human Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Oral Vaccine for Human Sales by Region (2021-2032)
  3. 6.2.1 Global Oral Vaccine for Human Sales by Region (2021-2026)
  4. 6.2.2 Global Oral Vaccine for Human Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Oral Vaccine for Human Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Oral Vaccine for Human Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Oral Vaccine for Human Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Oral Vaccine for Human Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Oral Vaccine for Human Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Oral Vaccine for Human Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Oral Vaccine for Human Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Oral Vaccine for Human Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Oral Vaccine for Human Revenue by Region
  1. 7.1 Global Oral Vaccine for Human Revenue by Region
  2. 7.1.1 Global Oral Vaccine for Human Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Oral Vaccine for Human Revenue by Region (2021-2026)
  4. 7.1.3 Global Oral Vaccine for Human Revenue by Region (2027-2032)
  5. 7.1.4 Global Oral Vaccine for Human Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Oral Vaccine for Human Revenue (2021-2032)
  8. 7.2.2 North America Oral Vaccine for Human Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Oral Vaccine for Human Revenue (2021-2032)
  11. 7.3.2 Europe Oral Vaccine for Human Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Oral Vaccine for Human Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Oral Vaccine for Human Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Oral Vaccine for Human Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Oral Vaccine for Human Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Bibcol
  2. 8.1.1 Bibcol Company Information
  3. 8.1.2 Bibcol Business Overview
  4. 8.1.3 Bibcol Oral Vaccine for Human Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Bibcol Oral Vaccine for Human Product Portfolio
  6. 8.1.5 Bibcol Recent Developments
  7. 8.2 Bio-Med
  8. 8.2.1 Bio-Med Company Information
  9. 8.2.2 Bio-Med Business Overview
  10. 8.2.3 Bio-Med Oral Vaccine for Human Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Bio-Med Oral Vaccine for Human Product Portfolio
  12. 8.2.5 Bio-Med Recent Developments
  13. 8.3 EuBiologics
  14. 8.3.1 EuBiologics Company Information
  15. 8.3.2 EuBiologics Business Overview
  16. 8.3.3 EuBiologics Oral Vaccine for Human Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 EuBiologics Oral Vaccine for Human Product Portfolio
  18. 8.3.5 EuBiologics Recent Developments
  19. 8.4 Halfkin Bio-Pharmaceuticals
  20. 8.4.1 Halfkin Bio-Pharmaceuticals Company Information
  21. 8.4.2 Halfkin Bio-Pharmaceuticals Business Overview
  22. 8.4.3 Halfkin Bio-Pharmaceuticals Oral Vaccine for Human Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Halfkin Bio-Pharmaceuticals Oral Vaccine for Human Product Portfolio
  24. 8.4.5 Halfkin Bio-Pharmaceuticals Recent Developments
  25. 8.5 Panacea Biotec Ltd
  26. 8.5.1 Panacea Biotec Ltd Company Information
  27. 8.5.2 Panacea Biotec Ltd Business Overview
  28. 8.5.3 Panacea Biotec Ltd Oral Vaccine for Human Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Panacea Biotec Ltd Oral Vaccine for Human Product Portfolio
  30. 8.5.5 Panacea Biotec Ltd Recent Developments
  31. 8.6 PaxVax
  32. 8.6.1 PaxVax Company Information
  33. 8.6.2 PaxVax Business Overview
  34. 8.6.3 PaxVax Oral Vaccine for Human Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 PaxVax Oral Vaccine for Human Product Portfolio
  36. 8.6.5 PaxVax Recent Developments
  37. 8.7 Serum Institute
  38. 8.7.1 Serum Institute Company Information
  39. 8.7.2 Serum Institute Business Overview
  40. 8.7.3 Serum Institute Oral Vaccine for Human Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Serum Institute Oral Vaccine for Human Product Portfolio
  42. 8.7.5 Serum Institute Recent Developments
  43. 8.8 Vabiotech
  44. 8.8.1 Vabiotech Company Information
  45. 8.8.2 Vabiotech Business Overview
  46. 8.8.3 Vabiotech Oral Vaccine for Human Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Vabiotech Oral Vaccine for Human Product Portfolio
  48. 8.8.5 Vabiotech Recent Developments
  49. 8.9 Valneva
  50. 8.9.1 Valneva Company Information
  51. 8.9.2 Valneva Business Overview
  52. 8.9.3 Valneva Oral Vaccine for Human Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Valneva Oral Vaccine for Human Product Portfolio
  54. 8.9.5 Valneva Recent Developments
  55. 8.10 Tiantan Biological
  56. 8.10.1 Tiantan Biological Company Information
  57. 8.10.2 Tiantan Biological Business Overview
  58. 8.10.3 Tiantan Biological Oral Vaccine for Human Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Tiantan Biological Oral Vaccine for Human Product Portfolio
  60. 8.10.5 Tiantan Biological Recent Developments
  61. 8.11 GSK
  62. 8.11.1 GSK Company Information
  63. 8.11.2 GSK Business Overview
  64. 8.11.3 GSK Oral Vaccine for Human Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 GSK Oral Vaccine for Human Product Portfolio
  66. 8.11.5 GSK Recent Developments
  67. 8.12 Merck
  68. 8.12.1 Merck Company Information
  69. 8.12.2 Merck Business Overview
  70. 8.12.3 Merck Oral Vaccine for Human Sales, Price, Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Merck Oral Vaccine for Human Product Portfolio
  72. 8.12.5 Merck Recent Developments
  73. 8.13 Sanofi
  74. 8.13.1 Sanofi Company Information
  75. 8.13.2 Sanofi Business Overview
  76. 8.13.3 Sanofi Oral Vaccine for Human Sales, Price, Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Sanofi Oral Vaccine for Human Product Portfolio
  78. 8.13.5 Sanofi Recent Developments
  79. 8.14 Shanghai United Cell
  80. 8.14.1 Shanghai United Cell Company Information
  81. 8.14.2 Shanghai United Cell Business Overview
  82. 8.14.3 Shanghai United Cell Oral Vaccine for Human Sales, Price, Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Shanghai United Cell Oral Vaccine for Human Product Portfolio
  84. 8.14.5 Shanghai United Cell Recent Developments
  85. 8.15 Lanzhou Institute
  86. 8.15.1 Lanzhou Institute Company Information
  87. 8.15.2 Lanzhou Institute Business Overview
  88. 8.15.3 Lanzhou Institute Oral Vaccine for Human Sales, Price, Revenue and Gross Margin (2021-2026)
  89. 8.15.4 Lanzhou Institute Oral Vaccine for Human Product Portfolio
  90. 8.15.5 Lanzhou Institute Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Oral Vaccine for Human Value Chain Analysis
  2. 9.1.1 Oral Vaccine for Human Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Oral Vaccine for Human Production Mode & Process
  6. 9.2 Oral Vaccine for Human Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Oral Vaccine for Human Distributors
  9. 9.2.3 Oral Vaccine for Human Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst